Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
Lexeo Therapeutics has filed an S-3/A shelf registration statement for the resale of up to 41,630,514 shares of common stock by selling stockholders. The shares include 20,790,120 outstanding shares, 6,963,556 shares issuable from pre-funded warrants, and 13,876,838 shares from common warrants issued in a private placement on May 27, 2025.
The company is advancing genetic medicine treatments for cardiovascular diseases. Key highlights:
- LX2006 for Friedreich ataxia cardiomyopathy shows promising Phase 1/2 results with improvements in cardiac biomarkers and frataxin protein expression
- LX2020 for PKP2 arrhythmogenic cardiomyopathy is in Phase 1/2 trials
- FDA alignment achieved on accelerated approval pathway with co-primary endpoints
As an emerging growth company and smaller reporting company, Lexeo's stock trades on Nasdaq under LXEO with last quoted price of $4.19 on June 25, 2025. The company will not receive proceeds from the stock sales but will receive proceeds from any warrant exercises.